ArticleScientific reports2026
Diagnostic and prognostic value of serum miR-155 in chronic obstructive pulmonary disease.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
We investigated serum miR-155 in chronic obstructive pulmonary disease (COPD) and its clinical utility. miR-155 in peripheral blood mononuclear cells (PBMCs) and serum cytokines (IL-1β, IL-6, IL-8, TNF-α) were quantified, and associations with disease occurrence, inflammation, severity, and prognosis were assessed over one year. A total of 117 participants were enrolled: 59 COPD patients (29 acute exacerbation [AECOPD], 30 stable), 31 heavy smokers, and 27 healthy controls. miR-155 was measured by RT-PCR and cytokines by ELISA. COPD patients were prospectively followed and categorized as frequent exacerbators (FE) or non-frequent exacerbators (NFE) to evaluate miR-155's predictive value. miR-155 was significantly elevated in COPD and heavy-smoking groups versus controls (P < 0.01) and higher in AECOPD than stable COPD (P < 0.01). ROC analysis identified optimal cutoff 0.578 (sensitivity 68.97%, specificity 96.67%, AUC = 0.8724). In AECOPD, miR-155 was lower in invasive pulmonary aspergillosis (IPA) than non-IPA patients (P < 0.01). All inflammatory cytokines were significantly elevated in AECOPD versus other groups (P < 0.01). miR-155 showed positive correlations with IL-1β (R = 0.22, 95% CI 0.03-0.39, P < 0.05), IL-6 (R = 0.20, 95% CI 0.01-0.37, P < 0.05), IL-8 (R = 0.20, 95% CI 0.02-0.37, P < 0.05), TNF-α (R = 0.22, 95% CI 0.04-0.39, P < 0.05), GOLD stage (R = 0.35, 95% CI 0.10-0.55, P < 0.01), and ABE grouping (R = 0.66, 95% CI 0.49-0.79, P < 0.01). FE patients had higher miR-155 than NFE (P < 0.001), with moderate correlation to exacerbation frequency (R = 0.63, 95% CI 0.45-0.76, P < 0.01). miR-155 is involved in smoking-related COPD pathogenesis and shows promise as a biomarker for identifying AECOPD and differentiating IPA from non-IPA infections. Its correlations with inflammatory cytokines and disease severity support its utility in assessing inflammatory burden and clinical severity. Elevated miR-155 predicts frequent exacerbations, highlighting its potential as a prognostic biomarker.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.